Obviousness-Type Double Patenting: Navigating the Ever-Changing Landscape
Presented by The Knowledge Group
The emergence of new court rulings continues to shape the applicability and scope of the obviousness-type double patenting (ODP) doctrine, which is meant to prevent patentees from unjustly extending patent rights by owning multiple patents on the same invention. Recently, the U.S. Court of Appeals for the Federal Circuit issued two significant decisions - Novartis AG v. Ezra Ventures LLC and Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical Inc. - which provide guidance on when ODP does not invalidate patent term extensions (PTEs).
Counsel to patent applicants and owners should be in the know of the recent court rulings and other developments involving ODP to better manage potential threats and opportunities regarding patent term and validity.
In this live webcast, a panel of distinguished professionals and thought leaders brought together by The Knowledge Group will provide patent practitioners with an in-depth analysis of the evolving ODP landscape. They will examine the implications of Ezra and Breckenridge and other ODP updates while offering insights on how to best protect a client’s interests from significant ODP issues.
Some of the major topics that will be covered in this course are:
- Obviousness-Type Double Patenting (ODP) Rejections: Statistics
- Recent Court Rulings:
- Novartis AG v. Ezra Ventures LLC
- Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical Inc.
- Implications of Recent Trends and Developments
- Managing Potential Threats and Opportunities
- Best Practices and Strategies
CLE credit available.